Qatar Cardiometabolic Registry
Qatar Cardiometabolic Registry
Type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) are closely related. T2DM
 risk equivalent for CVD and it remains the major cause of death in T2DM. Thus, patients with
 T2DM and CVD disease are at very high-risk of CVD-related mortality. Therefore, more
 aggressive metabolic and hemodynamic control is required in such patients to improve the
 prognosis. We recently initiated a cardio-metabolic clinical service at the Heart Hospital,
 where T2DM patients with existing CVD are simultaneously examined by Cardiologist and
 Diabetologist for optimal metabolic and hemodynamic control. We would like to start a
 clinical registry for all patients who attend this clinical service to collect import
 clinical data about this population. This registry will serve an important source for future
 clinical research in the field.
Various investigators have shown that type 2 diabetes is associated with out-of-hospital
 cardiac arrest and mortality due sudden cardiac arrest [1,2]. In comparison to non-diabetic
 patients, those with T2DM possess greater risk of cardiovascular morbidity and deaths, and
 are considerably influenced by cardiovascular disease [3]. To assess the potential benefit of
 T2DM prevention and treatment, as well as the future burden of T2DM-associated diseases can
 help in better understanding of the T2DM and the risk of chronic cardiovascular
 manifestations is warranted [4]. Herein, we would like to start a clinical registry for all
 patients who attend this clinical service to collect import clinical data about this
 population. This registry will serve an important source for scientific information that can
 be used in future to design clinical research studies for better patient care and management.

 The cardio-metabolic clinic has been recently established in the Heart Hospital to provide
 state-of-the-art care for patients with T2DM and established heart disease, e.g. ischemic
 heart disease, heart failure, etc. the health information of all patients attending the
 cardio-metabolic Clinic for the care of their disease who provide their consent for the use
 of their health information in the registry will be added to the registry.

 A data base for this registry will be created in Cerner which will be password protected.
 Clinical information about patients attending the cardiometabolic clinic in the Heart
 Hospital will be collected. Data will include demographics (age, gender, and nationality),
 vital signs (Pulse rate, blood pressure), waist circumference , Weight, Canadian
 Cardiovascular Society (CCS) Class, New York Heart Association ( NYHA) class, history of
 hospitalization for chest pain, shortness of death, Stent thrombosis, syncope or Dizzy
 spells, Stroke, Transient Ischemic Attack (TIA), Polyurea, urinary tract infection, Activity
 Level, Foot exam, Peripheral pulses, Mono-filament exam, Ankle Brachial Index test, Cardiac
 Rehabilitation, Diabetes monitoring at home, Insulin Pump, Revascularization Needed,
 angiogram and presentation (Presenting Acute Coronary Syndrome (ACS), ST-Elevation Myocardial
 Infarction (STEMI), Upstream antiplatelets, Culprit artery, Non-ST-Elevation Myocardial
 Infarction (NSTEMI), Stent-No1, Unstable angina, Known Diabetes, Stent-No2, Newly diagnosed
 DM, Stent-No3, Hypertension, Total No of Stent, Tobacco use, Type of Stent, Thrombectomy,
 Troponin highest level, EUROScore, Reopro, Coronary angiogram, Thrombosis in Myocardial
 Infarction (TIMI) flow, Dissection, Perforation, Syntax Score Coronary Artery Disease
 (SYNTAXSCORE), Left Main Coronary Artery (LM), Loss of side branch, Access type, Left
 Anteriour Descending Artery (LAD), D1, Seal Device, D2, Left Circumflex (LCx), First Obtuse
 Marginal (OM1), Second Obtuse marginal (OM2), Right CoronaryArtery (RCA), Patent Ductus
 Arteriosus (PDA), Percutaneous Coronary Intervention (PCI), PCI-LAD, PCI-D1, PCI-D2, PCI-LCx,
 PCI-OM1, PCI-OM2, PCI-RCA, PCI-PDA, Drug Eluted Stent (DES), Bare Metal Stent (BMS), BMS,
 Total number of stents, Coronary Artery Bypass Surgery (CABG), Trp post PCI-24, Creatinine-48
 post PCI, Stent thrombosis), laboratory findings, history of diabetes (type 1 and 2),
 Gastroparesis, Erectile dysfunction, Metabolic Syndrome, chronic kidney disease, Chronic
 Liver Disease, Gestational DM, Diabetic ketoacidosis, hypoglycemia, Hyperosmolar
 Hyperglycemic Syndrome, Depression, Hypertension, Peripheral Arterial disease, Peripheral
 Arterial Disease (PAD)- Acute limb ischemia, PAD-Claudication, PAD Critical Limb Ischemia,
 PAD-Cellulitis, PAD-Lower Limb osteomyelitis, Hemorrhage, Intracranial Hemorrhage, Stroke,
 Hemorrhagic, Ischemic, Carotid Endarterectomy, carotid Endarterectomy (CEA)-Left, CEA-Right,
 Carotid stenting, Amputation, Above knee Amputation, Amputation foot, Amputation of Toe, PAD
 Bypass, PAD intervention, medications.

 Study population:

 Inclusion criteria: patients with T2DM and established heart disease, such as ischemic heart
 disease, heart failure, etc. will be included in the study after obtaining the informed
 consent.

 Exclusion criteria: Subjects who do not have T2DM and existing heart disease will be excluded
 from the registry.

 The treating physicians will enter the list of patients attended his clinic to Power Trial.
 The study investigators will update the list of the patients attended the cardio-metabolic
 clinic on daily basis and the registry will transfer the information from the Cerner to the
 registry database. The clinical service has been start from September 15, 2017, and each
 patient who attended the clinic will be added to the registry.

 This registry is prospectively collecting the information from Cerner Clinical Viewer. For
 future research the investigators who wish to utilize the registry data for their research
 will have to seek Institutional Review Board (IRB) approval for their research proposal.

 Informed Consent Informed consent will be obtained from each patient who will attend the
 cardiometabolic clinic to allow us to capture his clinical information into the registry
 database.

 Subject Withdrawal/ Withdrawal of Consent If the subjects withdraw his consent, the
 information about his future follow-up visits in the clinic will not be added to the
 registry. However, previous data added to the registry will continue to be available.
Inclusion Criteria:

 -  Patients with type 2 diabetes mellitus

 -  Newly diagnosed heart disease, such as ischemic heart disease, heart failure.

 Exclusion Criteria:

 -  Patients who do not have type 2 diabetes mellitus

 -  Preexisting heart disease